Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 12, 2007, Pages 4678-4685

  Goldfine, Allison B ^a,b,c   Mun, E C ^b,c   Devine, E ^a   Bernier, R ^a   Baz Hecht, M ^a,b   Jones, D B ^b,d   Schneider, B E ^b,d   Holst, J J ^e   Patti, M E ^a,b  

^a JOSLIN DIABETES CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; INCRETIN; INSULIN;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; METABOLISM; MORBID OBESITY; OBESITY; POSTOPERATIVE COMPLICATION; POSTPRANDIAL STATE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STOMACH BYPASS; TEST MEAL;

EID: 36849063201     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-0918     Document Type: Article

References (47)

1. Pratt JS, Cummings S, Vineberg DA, Graeme-Cook F, Kaplan LM 2004 Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 25-2004. A 49-year-old woman with severe obesity, diabetes, and hypertension. N Engl J Med 351:696-705
2. DeMaria EJ 2007 Bariatric surgery for morbid obesity. N Engl J Med 356:2176-2183
3. Crookes PF 2006 Surgical treatment of morbid obesity. Annu Rev Med 57:243-264
4. Tritos NA, Mun E, Bertkau A, Grayson R, Maratos-Flier E, Goldfine A 2003 Serum ghrelin levels in response to glucose load in obese subjects post-gastric bypass surgery. Obes Res 11:919-924
5. Korner J, Bessler M, Cirilo LJ, Conwell IM, Daud A, Restuccia NL, Wardlow SL 2005 Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab 90:359-365
6. Chan JL, Mun EC, Stoyneva V, Mantzoros CS, Goldfine AB 2006 Peptide YY levels are elevated after gastric bypass surgery. Obesity (Silver Spring) 14:194-198
7. le Roux CW, Aylwin SJ, Batterham RL, Borg CM, Coyle F, Prasad V, Shurey S, Ghatei MA, Patel AG, Bloom SR 2006 Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 243:108-114
8. Wickremesekera K, Miller G, Naotunne TD, Knowles G, Stubbs RS 2005 Loss of insulin resistance after Roux-en-Y gastric bypass surgery: a time course study. Obes Surg 15:474-481
9. Service GJ, Thompson GB, Service FJ, Andrews JC, Collazo-Clavell ML, Lloyd RV 2005 Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 353:249-254
10. Patti ME, McMahon G, Mun EC, Bitton A, Holst JJ, Goldsmith J, Hanto DW, Callery M, Arky R, Nose V, Bonner-Weir S, Goldfine AB 2005 Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia 48:2236-2240
11. Clancy TE, Moore Jr FD, Zinner MJ 2006 Post-gastric bypass hyperinsulinism with nesidioblastosis: subtotal or total pancreatectomy may be needed to prevent recurrent hypoglycemia. J Gastrointest Surg 10:1116-1119
12. Meier JJ, Butler AE, Galasso R, Butler PC 2006 Hyperinsulinemic hypoglycemia after gastric bypass surgery is not accompanied by islet hyperplasia or increased beta-cell turnover. Diabetes Care 29:1554-1559
13. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus 2003 Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26(Suppl 1):S5-S20
14. Krarup T, Madsbad S, Moody AJ, Regeur L, Faber OK, Holst JJ, Sestoft L 1983 Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed type I (insulin-dependent) diabetics. J Clin Endocrinol Metab 56:1306-1312
15. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ 1994 Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43:535-539
16. Gebhard B, Holst JJ, Biegelmayer C, Miholic J 2001 Postprandial GLP-1, norepinephrine, and reactive hypoglycemia in dumping syndrome. Dig Dis Sci 46:1915-1923
17. Linehan IP, Weiman J, Hobsley M 1986 The 15-minute dumping provocation test. Br J Surg 73:810-812
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC 1985 Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
19. Matsuda M, DeFronzo RA 1999 Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462-1470
20. Service FJ, Natt N, Thompson GB, Grant CS, van Heerden JA, Andrews JC, Lorenz E, Terzic A, Lloyd RV 1999 Noninsulinoma pancreatogenous hypoglycemia: a novel syndrome of hyperinsulinemic hypoglycemia in adults independent of mutations in Kir6.2 and SUR1 genes. J Clin Endocrinol Metab 84:1582-1589
21. Kaczirek K, Soleiman A, Schindl M, Passler C, Scheuba C, Prager G, Kaserer K, Niederle B 2003 Nesidioblastosis in adults: a challenging cause of organic hyperinsulinism. Eur J Clin Invest 33:488-492
22. Miholic J, Orskov C, Holst JJ, Kotzerke J, Meyer HJ 1991 Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy. Dig Dis Sci 36:1361-1370
23. Miholic J, Orskov C, Holst JJ, Kotzerke J, Pichlmayr R 1993 Postprandial release of glucagon-like peptide-1, pancreatic glucagon, and insulin after esophageal resection. Digestion 54:73-78
24. Kulkarni RN, Bruning JC, Winnay JN, Postic C, Magnuson MA, Kahn CR 1999 Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 96:329-339
25. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, Perfetti R 2002 Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143:4397-4408
26. Borg CM, le Roux CW, Ghatei MA, Bloom SR, Patel AG, Aylwin SJ 2006 Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg 93:210-215
27. Morinigo R, Moize V, Musri M, Lacy AM, Navarro S, Marin JL, Delgado S, Casamitjana R, Vidal J 2006 Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 91:1735-1740
28. Rubino F, Gagner M, Gentileschi P, Kini S, Fukuyama S, Feng J, Diamond E 2004 The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 240:236-242
29. Toft-Nielsen M, Madsbad S, Holst JJ 1998 Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia. Diabetologia 41:1180-1186
30. Miholic J, Hoffmann M, Holst JJ, Lenglinger J, Mittlbock M, Bergmann H, Stacher G 2007 Gastric emptying of glucose solution and associated plasma concentrations of GLP-1, GIP, and PYY before and after fundoplication. Surg Endosc 21:309-314
31. Gedulin BR, Nikoulina SE, Smith PA, Gedulin G, Nielsen LL, Baron AD, Parkes DG, Young AA 2005 Exenatide (exendin-4) improves insulin sensitivity and {β}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 146:2069-2076
32. Carpenter T, Trautmann ME, Baron AD 2005 Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 353:2192-2194
33. Todd JF, Stanley SA, Roufosse CA, Bishop AE, Khoo B, Bloom SR, Meeran K 2003 A tumour that secretes glucagon-like peptide-1 and somatostatin in a patient with reactive hypoglycaemia and diabetes. Lancet 361:228-230
34. Drucker DJ 2006 The biology of incretin hormones. Cell Metab 3:153-165
35. Clements RH, Gonzalez QH, Long CI, Wittert G, Laws HL 2004 Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus. Am Surg 70:1-4
36. Laferrere B, Heshka S, Wang K, Khan Y, McGinty J, Teixeira J, Hart AB, Olivan B 2007 Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 30:1709-1716
37. Gunnarsson PT, Winzell MS, Deacon CF, Larsen MO, Jelic K, Carr RD, Ahren B 2006 Glucose-induced incretin hormone release and inactivation are differently modulated by oral fat and protein in mice. Endocrinology 147:3173-3180
38. Bellini F, Sammicheli L, Ianni L, Pupilli C, Serio M, Mannelli M 1998 Hypoglycemia unawareness in a patient with dumping syndrome: report of a case. J Endocrinol Invest 21:463-467
39. Yamamoto H, Mori T, Tsuchihashi H, Akabori H, Naito H, Tani T 2005 A possible role of GLP-1 in the pathophysiology of early dumping syndrome. Dig Dis Sci 50:2263-2267
40. Ukleja A 2005 Dumping syndrome: pathophysiology and treatment. Nutr Clin Pract 20:517-525
41. Vecht J, Masclee AA, Lamers CB 1997 The dumping syndrome. Current insights into pathophysiology, diagnosis and treatment. Scand J Gastroenterol Suppl 223:21-27
42. Li-Ling J, Irving M 2001 Therapeutic value of octreotide for patients with severe dumping syndrome - a review of randomised controlled trials. J Postgrad Med J 77:441-442
43. Vecht J, Lamers CB, Masclee AA 1999 Long-term results of octreotide-therapy in severe dumping syndrome. Clin Endocrinol (Oxf) 51:619-624
44. Scavini M, Pontiroli AE, Folli F 2005 Asymptomatic hyperinsulinemic hypoglycemia after gastric banding. N Engl J Med 353:2822-2823
45. Vilsboll T, Krarup T, Madsbad S, Holst JJ 2001 No reactive hypoglycaemia in type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose. Diabet Med 18:144-149
46. Knop FK, Vilsboll T, Larsen S, Madsbad S, Holst JJ, Krarup T 2003 No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis. Diabetes Care 26:2581-2587
47. Yoon KH, Ko SH, Cho JH, Lee JM, Ahn YB, Song KH, Yoo SJ, Kang MI, Cha BY, Lee KW, Son HY, Kang SK, Kim HS, Lee IK, Bonner-Weir S 2003 Selective β;-cell loss and α-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 88:2300-2308